Favorable outcome of ex-vivo purging of monocytes after the reintroduction of treatment after interruption in patients infected with multidrug resistant HIV-1

Journal of Medical Virology

Volumn 79, Issue 11, 2007, Pages 1640-1649

  Hasson, Hamid ^a   Mantelli, Barbara ^a   Biswas, Priscilla ^a   Malnati, Mauro ^a   Gianotti, Nicola ^a   Vecchi, Andrea ^a   Nozza, Silvia ^a   Cernuschi, Massimo ^a   Boeri, Enzo ^b   Clerici, Mario ^c   Lazzarin, Adriano ^d   Beretta, Alberto ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b Diagnostica and Ricerca San Raffaele   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Drug resistance; Monocytes; Purging; Treatment interruption

Indexed keywords

ABACAVIR; AMPRENAVIR; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

ADULT; APHERESIS; ARTICLE; BONE MARROW CELL; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; DEVICE; DRUG SENSITIVITY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; MALE; MONOCYTE; MULTIDRUG RESISTANCE; PURGING OF MYELOID CELL; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, MULTIPLE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LEUKAPHERESIS; MALE; MIDDLE AGED; MONOCYTES; RNA, VIRAL; TREATMENT OUTCOME;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 34748838636     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.20977     Document Type: Article

References (37)

1. Aquaro S, Perno CF, Balestra E, Balzarini J, Cenci A, Francesconi M, Panti S, Serra F, Villani N, Calio R. 1997. Inhibition of replication of HIV in primary monocyte/macrophages by different antiviral drugs and comparative efficacy in lymphocytes. J Leukoc Biol 62:138-143.
2. Aquaro S, Calio R, Balestra E, Bagarelli P, Cenci A, Bertoli A, Tavazzi B, Di Pierro D, Francesconi M, Abdelahad D, Perno CF. 1998. Clinical implications of HIV dynamics and drug resistance in macrophages. J Biol Reg Homeost Agents 12:23-27.
3. Beretta A, Hasson H, Saniabadi A, Alfano M, Trabattoni D, Lillo F, Ferrante P, Clerici M, Lazzarin A. 2002. Selective granulocyte/monocyte apheresis in the treatment of HIV-infected patients: Short-term and long-term effects on immunological and virological parameters. Perfusion 17:47-51.
4. Biswas P, Mantelli B, Sica A, Malnati M, Panzeri C, Saccani A, Hasson H, Vecchi A, Saniabadi A, Lusso P, Lazzarin A, Beretta A. 2003a. Expression of CD4 on Human peripheral blood neutrophils. Blood 101:4452-4456.
5. Biswas P, Mantelli B, Hasson H, Vecchi A, Saniabadi A, Lazzarin A, Beretta A. 2003b. In vivo modulation of leukocyte trafficking receptor following therapeutic purging of myeloid cells: Implications for treatment of HIV infection and other immune disorders. Clin Immunol 109:355-358.
6. D'Aquila RT, Schapiro JM, Brun-Vezinet F, Clotet B, Conway B, Demeter LM, Grant RM, Johnson VA, Kuritzkes DR, Loveday C, Shafer RW, Richman DD. 2003. Drug resistance mutations in HIV-1. Top HIV Med 11:92-96.
7. Deeks SG, Wrin T, Liegler T, Hoh R, Hayden M, Barbour JD, Hellmann NS, Petropoulos CJ, McCune JM, Hellerstein MK, Grant RM. 2001. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 344:472-480.
8. Delobel P, Sandres-Sauné K, Cazabat M, L'Faqihi FE, Aquilina C, Obadia M, Pasquier C, Marchou B, Massip P, Izopet J. 2005. Persistence of distinct HIV-1 populations in blood monocytes and naïve and memory CD4 T cells during prolonged suppressive HAART. AIDS 19:1739-1750.
9. Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick J, Pierson T, Smith K, Lisziewicz J, Lori F, Flexner C, Quinn TC, Chaisson RE, Rosenberg E, Walker B, Gange S, Gallant J, Siliciano RF. 1999. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 5:512-517.
10. Ghosn J, Wirden M, Ktorza N, Peytavin G, Aït-Mohand H, Schneider L, Dominguez S, Bricaire F, Calvez V, Costagliola D, Katlama C. 2005. No benefit of a structured treatment interruption based on genotypic resistance in heavily pretreated HIV-infected patients. AIDS 19:1643-1647.
11. Gianotti N, Soria A, Galli L, Castagna A, Cernuschi M, Hasson H, Lazzarin A. 2004. Predictors of sustained response to therapy resumption after treatment interruption in HIV-infected patients failing antiretroviral therapy. J Med Virol 72:181-186.
12. Hance AJ, Lemiale V, Izopet J, Lecossier D, Joly V, Massip P, Mammano F, Descamps D, Brun-Vezinet F, Clavel F. 2001. Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy. J Virol 75:6410-6417.
13. Hasson H, Saniabadi A, Alfano M, Trabattoni D, Ferrante P, Lillo F, Clerici M, Lazzarin A, Beretta A. 2002. Granulocyte/monocyte apheresis induces sustained increase in CD4 T cells in HIV-1 infected patients with poor CD4 T cell restoration after suppression of viral replication by HAART. J Biol Reg Homeost Agents 16:58-63.
14. Igarashi T, Brown CR, Endo Y, Buckler-White A, Plishka R, Bischofberger N, Hirsch V, Martin MA. 2001. Macrophage are the principal reservoir and sustain high virus loads in rhesus macaques after the depletion of CD4+ T cells by a high pathogenic simian immunodeficiency virus/HIV type 1 cbimera (SHIV): Implications for HIV-1 infections of humans. Proc Natl Acad Science USA 98:658-663.
15. Jaafar A, Massip P, Sandres-Sauné K, Souyris C, Pasquier C, Aquilina C, Izopet J. 2004. HIV therapy after treatment interruption in patients with multiple failure and more than 200 CD4+ T lymphocyte count. J Med Virol 74:8-15.
16. Kashiwagi N, Hirata I, Kasukawa R. 1998. A role for granulocyte and monocyte apheresis in the treatment of rheumatoid arthritis. Ther Apher 2:134-141.
17. Kashiwagi N, Sugimura K, Koiwai H, Yamamoto H, Yoshikawa T, Saniabadi AR, Adachi M, Shimoyama T. 2002. Immunomodulatory effects of granulocyte and monocyte adsorption apheresis as a treatment for patients with ulcerative colitis. Dig Dis Sci 47:1334-1341.
18. Katlama C, Dominguez S, Gourlain K, Duvivier C, Delaugerre C, Legrand M, Tubiana R, Reynes J, Molina JM, Peytavin G, Calvez V, Costagliola D. 2004. Benefit of treatment interruption in HIV-infected patients with multiple therapeutic failures: A randomized controlled trial (ANRS 097). AIDS 18:217-226.
19. Lambotte O, Taoufik Y, de Goer MG, Wallon C, Goujard C, Delfraissy JF. 2000. Detection of infectious HIV in circulating monocytes from
20. patients on prolonged highly antiretroviral therapy. J AIDS 23: 114-119.
21. Lawrence J, Mayers DL, Hullsiek KH, Collins G, Abrams DI, Reisler RB, Crane LR, Schroetter BS, Dionne TJ, Saldanha JM, Jones MC, Baxter JD, 064 Study Team of the Terry Beim Community Programs for Clinical Research on AIDS. 2003. Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. N Engl J Med 349:837-846.
22. Lazzarin A, Clerici M, Hasson H, Fumagalli L, Ferrante P, Saniabadi AR, Adachi M, Beretta A. 2001. Immunovirological improvement in partially HAART responder HIV-infected patients by monocyte adsorption apheresis. J Clin Apher 16:35-36.
23. Maggiolo F, Ripamonti D, Gregis G, Quinzan G, Callegaro A, Suter F. 2004. Effect of prolonged discontinuation of successful antiretroviral therapy on CD4 T cells: A controlled, prospective trial. AIDS 18:439-446.
24. Miller V, Sabin C, Hertogs K, Bloor S, Martinez-Picado J, DAquila R, Larder B, Lutz T, Gute P, Weidmann E, Rabenau H, Phillips A, Staszewski S. 2000. Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure. AIDS 14:2857-2867.
25. Pellegrin I, Thiebaut R, Blanco P, Viallard JF, Schrive MH, Merel P, Chene G, Fleury H, Moreau JF, Pellegrin JL. 2005. Can highly active antiretroviral therapy be interrupted in patients with sustained moderate HIV RNA and >400 CD4+ cells/microl? Impact on immunovirological parameters. J Med Virol 77:164-172.
26. Perno CF, Newcomb FM, Davis DA, Aquaro S, Humphrey RW, Calio R, Yarchoan R. 1998. Relative potency of protease inhibitors in monocytes/macrophages acutely and chronically infected with human immunodeficiency virus. J Inf Dis 178:413-422.
27. Pomerantz R, Lafeuillade A. 2004. Organizing Committee. First international workshop on HIV-1 persistance during therapy. HIV Clin Trials 5:40-49.
28. Ruiz L, Ribera E, Bonjoch A, Romeu J, Martinez-Picado J, Paredes R, Diaz M, Marfil S, Negredo E, Garcia-Prado J, Tural C, Sirera G, Clotet B. 2003. Role of structured treatment interruption before a 5-drug salvage antiretroviral regimen: The Retrogene Study. J Inf Dis 188:977-985.
29. Salvatori F, Locatellli G, Volpi R, Lusso P, Malnati M, Scarlatti G. 1999. emi-automated real time quantitative PCR of HIV-1 strains of diverse geographical origin. 4th European Conference on Experimental AIDS Research. 18-21 June, Tampere, Finland, Europe. Abstract 112.
30. Shafer RW. 2002. Genotypic testing for human immunodeficiency virus type 1 drug resistance. Clin Microb Rev 15:247-277.
31. Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, Margolick JB,
32. Kovacs C, Gange SJ, Siliciano RF. 2003. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 9:727-728.
33. Staszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, Skiest D, Stanford J, Stryker R, Johnson P, Labriola DF, Farina D, Manion DJ, Ruiz NM. 1999. Efavirenz plus Zidovudine and Lamivudine, Efavirenz plus Indinavir, and Indinavir plus Zidovudine and Lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med 341:1865-1873.
34. Venturi G, Romano L, Carli T, Corsi P, Pippi L, Valensin PE, Zazzi M. 2002. Divergent distribution of HIV-1 drug-resistant variants on and off antiretroviral therapy. Antiviral Ther 7:245-250.
35. Verhofstede C, Wanzeele FV, Van Der Gucht B, De Cabooter N, Plum J. 1999. Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype. AIDS 13:2541-2546.
36. Walmsley S, Bernstein B, King M, Arribas J, Beall G, Ruane P, Johnson M, Johnson D, Lalonde R, Japour A, Brun S, Sun E, M98-863 Study Team. 2002. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 346:2039-2046.
37. Zhu T, Muthui D, Holte S, Nickle D, Feng F, Brodie S, Hwangbo Y, Mullins JI, Corey L. 2002. Evidence for human immunodeficiency virus type 1 replication in vivo in CD14+ monocytes and its potential role as a source of virus in patients on highly active antiretroviral therapy. J Virol 76:707-716.